JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 42.87 Billion JPY | 24.83% |
| 2022 | 34.34 Billion JPY | -32.77% |
| 2021 | 51.08 Billion JPY | 69.79% |
| 2020 | 30.08 Billion JPY | 21.4% |
| 2019 | 24.78 Billion JPY | 7.0% |
| 2018 | 23.16 Billion JPY | 12.46% |
| 2017 | 20.59 Billion JPY | 13.87% |
| 2016 | 18.08 Billion JPY | 3.71% |
| 2015 | 17.43 Billion JPY | 3.46% |
| 2014 | 16.85 Billion JPY | 7.32% |
| 2013 | 15.7 Billion JPY | 11.39% |
| 2012 | 14.09 Billion JPY | 9.77% |
| 2011 | 12.84 Billion JPY | -11.16% |
| 2010 | 14.45 Billion JPY | 0.49% |
| 2009 | 14.38 Billion JPY | 19.07% |
| 2008 | 12.08 Billion JPY | 1.78% |
| 2007 | 11.87 Billion JPY | 38.94% |
| 2006 | 8.54 Billion JPY | 11.71% |
| 2005 | 7.64 Billion JPY | -5.57% |
| 2004 | 8.09 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 8.51 Billion JPY | 24.57% |
| 2024 Q1 | 8.14 Billion JPY | 41.34% |
| 2023 Q3 | 9.44 Billion JPY | -29.84% |
| 2023 Q4 | 9.15 Billion JPY | -3.1% |
| 2023 FY | 42.87 Billion JPY | 24.83% |
| 2023 Q1 | 10.8 Billion JPY | 41.34% |
| 2023 Q2 | 13.46 Billion JPY | 24.57% |
| 2022 Q4 | 7.64 Billion JPY | -31.2% |
| 2022 FY | 34.34 Billion JPY | -32.77% |
| 2022 Q1 | 9.6 Billion JPY | -11.15% |
| 2022 Q2 | 5.97 Billion JPY | -37.8% |
| 2022 Q3 | 11.11 Billion JPY | 86.03% |
| 2021 Q4 | 10.81 Billion JPY | -9.04% |
| 2021 Q3 | 11.88 Billion JPY | -35.99% |
| 2021 FY | 51.08 Billion JPY | 69.79% |
| 2021 Q1 | 9.81 Billion JPY | -7.95% |
| 2021 Q2 | 18.57 Billion JPY | 89.24% |
| 2020 Q3 | 8.47 Billion JPY | 46.85% |
| 2020 Q4 | 10.66 Billion JPY | 25.82% |
| 2020 FY | 30.08 Billion JPY | 21.4% |
| 2020 Q1 | 5.18 Billion JPY | -22.72% |
| 2020 Q2 | 5.77 Billion JPY | 11.37% |
| 2019 Q3 | 6.84 Billion JPY | 12.5% |
| 2019 Q2 | 6.08 Billion JPY | 17.96% |
| 2019 Q1 | 5.15 Billion JPY | -32.46% |
| 2019 FY | 24.78 Billion JPY | 7.0% |
| 2019 Q4 | 6.7 Billion JPY | -2.0% |
| 2018 FY | 23.16 Billion JPY | 12.46% |
| 2018 Q2 | 5.59 Billion JPY | 19.69% |
| 2018 Q3 | 5.25 Billion JPY | -6.16% |
| 2018 Q4 | 7.63 Billion JPY | 45.29% |
| 2018 Q1 | 4.67 Billion JPY | -12.51% |
| 2017 Q2 | 5.8 Billion JPY | 32.26% |
| 2017 FY | 20.59 Billion JPY | 13.87% |
| 2017 Q4 | 5.34 Billion JPY | 5.63% |
| 2017 Q3 | 5.06 Billion JPY | -12.76% |
| 2017 Q1 | 4.38 Billion JPY | -12.0% |
| 2016 Q2 | 4.73 Billion JPY | 24.51% |
| 2016 Q1 | 3.8 Billion JPY | -13.27% |
| 2016 FY | 18.08 Billion JPY | 3.71% |
| 2016 Q4 | 4.98 Billion JPY | 9.15% |
| 2016 Q3 | 4.56 Billion JPY | -3.52% |
| 2015 Q1 | 4.14 Billion JPY | -8.62% |
| 2015 Q4 | 4.38 Billion JPY | 2.59% |
| 2015 FY | 17.43 Billion JPY | 3.46% |
| 2015 Q3 | 4.27 Billion JPY | -7.82% |
| 2015 Q2 | 4.63 Billion JPY | 11.73% |
| 2014 FY | 16.85 Billion JPY | 7.32% |
| 2014 Q2 | 4.34 Billion JPY | 13.97% |
| 2014 Q3 | 4.16 Billion JPY | -4.21% |
| 2014 Q4 | 4.53 Billion JPY | 9.09% |
| 2014 Q1 | 3.81 Billion JPY | -6.21% |
| 2013 Q3 | 4.29 Billion JPY | 8.94% |
| 2013 Q4 | 4.06 Billion JPY | -5.43% |
| 2013 Q2 | 3.94 Billion JPY | 16.02% |
| 2013 Q1 | 3.39 Billion JPY | -15.6% |
| 2013 FY | 15.7 Billion JPY | 11.39% |
| 2012 Q2 | 3.44 Billion JPY | 8.46% |
| 2012 Q4 | 4.02 Billion JPY | 16.9% |
| 2012 FY | 14.09 Billion JPY | 9.77% |
| 2012 Q1 | 3.17 Billion JPY | 0.96% |
| 2012 Q3 | 3.44 Billion JPY | -0.04% |
| 2011 Q3 | 3.31 Billion JPY | 0.57% |
| 2011 Q2 | 3.29 Billion JPY | 6.74% |
| 2011 Q1 | 3.08 Billion JPY | -21.74% |
| 2011 FY | 12.84 Billion JPY | -11.16% |
| 2011 Q4 | 3.14 Billion JPY | -5.0% |
| 2010 Q1 | 3.91 Billion JPY | -3.03% |
| 2010 Q4 | 3.94 Billion JPY | 13.46% |
| 2010 FY | 14.45 Billion JPY | 0.49% |
| 2010 Q3 | 3.47 Billion JPY | 11.26% |
| 2010 Q2 | 3.12 Billion JPY | -20.1% |
| 2009 Q3 | 4.31 Billion JPY | 57.05% |
| 2009 Q4 | 4.03 Billion JPY | -6.59% |
| 2009 FY | 14.38 Billion JPY | 19.07% |
| 2009 Q2 | 2.74 Billion JPY | -16.34% |
| 2009 Q1 | 3.28 Billion JPY | -1.94% |
| 2008 Q4 | 3.35 Billion JPY | -5.68% |
| 2008 FY | 12.08 Billion JPY | 1.78% |
| 2008 Q3 | 3.55 Billion JPY | 32.29% |
| 2008 Q2 | 2.68 Billion JPY | 0.0% |
| 2007 FY | 11.87 Billion JPY | 38.94% |
| 2006 FY | 8.54 Billion JPY | 11.71% |
| 2005 FY | 7.64 Billion JPY | -5.57% |
| 2004 FY | 8.09 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 442.23 Billion JPY | 90.306% |
| Astellas Pharma Inc. | 1603.67 Billion JPY | 97.327% |
| Chugai Pharmaceutical Co., Ltd. | 1111.36 Billion JPY | 96.142% |
| Ono Pharmaceutical Co., Ltd. | 502.67 Billion JPY | 91.471% |
| Santen Pharmaceutical Co., Ltd. | 301.96 Billion JPY | 85.803% |
| Daiichi Sankyo Company, Limited | 1601.68 Billion JPY | 97.323% |
| Otsuka Holdings Co., Ltd. | 2018.56 Billion JPY | 97.876% |
| Perseus Proteomics Inc. | 100.4 Million JPY | -42599.349% |